MAP2K7 and melanoma: Although a decreasing trend in fatal melanoma cases is observed in the United States and the majority of European countries [14,15], as a result of early detection and the clinical use of the BRAFV600/MEK inhibitors and immune checkpoint inhibitors for advanced stage melanomas [16,17], the incidence and mortality rates are still unacceptably high [14,18].